ReviewFrontiers in oncology2023
The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy.
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Remodeling the marrow fat niche: BMAT in cancer bone metastases and hematological malignancies.Current opinion in endocrine and metabolic research · 2026Article
- Association study of aromatase inhibitors and adverse events related to osteoporosis: based on pharmacovigilance data.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Real-world pharmacovigilance of drug-related bone metabolism disorders: integrating FAERS and VigiAccess with a Bradford Hill-based causal plausibility assessment.Frontiers in pharmacology · 2026Article
- Adherence and Compliance with Endocrine Treatment After Primary Breast Cancer Treatment: A Cross-Sectional Qualitative Study.Medicina (Kaunas, Lithuania) · 2025Article
- Efficacy of denosumab versus alendronate for aromatase inhibitor-associated osteoporosis in postmenopausal breast cancer patients: a retrospective analysis.BMC musculoskeletal disorders · 2025Article
- A comprehensive review and advanced biomolecule-based therapies for osteoporosis.Journal of advanced research · 2025Review
- Research Status and Hot Spot Visualization Analysis of Osteoporosis from 2014 to 2025.Journal of multidisciplinary healthcare · 2025Article
- Course of Vitamin D Levels in Newly Diagnosed Non-Metastatic Breast Cancer Patients over One Year with Quarterly Controls and Substitution.Nutrients · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a significant global health concern, and the discovery of endocrine therapy has played a crucial role in the treatment of estrogen-positive breast cancer. However, these therapies are often associated with osteoporosis-related adverse events, which increase the risk of fractures in breast cancer patients and can result in limited mobility and reduced quality of life. Previous studies have shown that osteoporosis is essential side effects of the breast cancer therapy, although the exact mechanisms remain mostly unclear. Current clinical treatments, such as bisphosphonates, cause side effects and may impact the therapeutic response to endocrine drugs. In this review, we explore the likelihood of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy and discuss the involved mechanisms as well as the therapeutic potential of drugs and drug combination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.